Can an immunotherapy combo shrink lung tumors before surgery? a phase 3 trial aims to find out.

NCT ID NCT04158440

Completed Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Participants receive either toripalimab plus chemotherapy or a placebo plus chemotherapy, followed by surgery. The study measures how well the tumor responds and how long patients remain cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (an immunotherapy drug) combined with platinum-based chemotherapy
What this could lead to: If successful, this approach could become a new standard treatment to shrink lung tumors before surgery, potentially improving survival and reducing recurrence.
What could go wrong: This is an early-phase trial, and the combination may cause significant side effects like immune-related inflammation. It is not yet proven to be better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates